HK102996A - Pankreatin preparations - Google Patents

Pankreatin preparations

Info

Publication number
HK102996A
HK102996A HK102996A HK102996A HK102996A HK 102996 A HK102996 A HK 102996A HK 102996 A HK102996 A HK 102996A HK 102996 A HK102996 A HK 102996A HK 102996 A HK102996 A HK 102996A
Authority
HK
Hong Kong
Prior art keywords
pankreatin
preparations
mass
pancreatin
solvent
Prior art date
Application number
HK102996A
Other languages
English (en)
Inventor
Guenther Atzl
Franz Langer
Herbert Polleres
Original Assignee
Biochemie Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biochemie Gmbh filed Critical Biochemie Gmbh
Publication of HK102996A publication Critical patent/HK102996A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK102996A 1989-11-24 1996-06-13 Pankreatin preparations HK102996A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT268889 1989-11-24

Publications (1)

Publication Number Publication Date
HK102996A true HK102996A (en) 1996-06-21

Family

ID=3538711

Family Applications (1)

Application Number Title Priority Date Filing Date
HK102996A HK102996A (en) 1989-11-24 1996-06-13 Pankreatin preparations

Country Status (13)

Country Link
US (2) US5674532A (ko)
EP (1) EP0436110B1 (ko)
JP (1) JP3025528B2 (ko)
KR (1) KR100229754B1 (ko)
AT (1) ATE102026T1 (ko)
AU (1) AU638784B2 (ko)
CA (1) CA2030581C (ko)
DE (1) DE69007055T2 (ko)
DK (1) DK0436110T3 (ko)
ES (1) ES2050340T3 (ko)
HK (1) HK102996A (ko)
PH (1) PH30058A (ko)
WO (1) WO1991007948A1 (ko)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9101090D0 (sv) * 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
US5260074A (en) * 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
AU6123296A (en) * 1995-05-31 1996-12-18 Akzo Nobel N.V. Enteric coated compressed pancreatin particles
US5861291A (en) * 1997-02-24 1999-01-19 Biozymes Inc. Method for producing pancreatin which contains low amounts of residual organic solvent and product thereof
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
US7122207B2 (en) 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
KR100367659B1 (ko) * 2000-05-08 2003-01-14 주식회사 바이넥스 선택적 안정화제의 첨가에 따른 자가분해(autolysis)를 통한 고역가 판크레아틴의 제조방법
US20070053895A1 (en) * 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US7153504B2 (en) * 2004-07-30 2006-12-26 Can Technologies, Inc. Stabilized pancreas product
JP5140586B2 (ja) 2005-07-29 2013-02-06 アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング 滅菌パンクレアチン粉末の製法
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US20080058282A1 (en) * 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
US20090117180A1 (en) * 2007-02-20 2009-05-07 Giovanni Ortenzi Stable digestive enzyme compositions
US8221747B2 (en) * 2007-02-20 2012-07-17 Aptalis Pharma Limited Stable pancreatic enzyme compositions
US10087493B2 (en) 2008-03-07 2018-10-02 Aptalis Pharma Canada Ulc Method for detecting infectious parvovirus in pharmaceutical preparations
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US11016104B2 (en) 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
EP2165717A1 (de) 2008-08-27 2010-03-24 Nordmark Arzneimittel GmbH & Co.KG Verfahren zur Verringerung der viralen und mikrobiellen Belastung feststoffhaltiger biologischer Extrakte
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
DK3064217T3 (en) 2009-01-06 2018-05-28 Galenagen Llc COMPOSITIONS COMPREHENSIVE PROTEASE, AMYLASE AND LIPASE FOR USE IN TREATMENT OF STAPHYLOCOCCUS AUREUS INFECTIONS
EP2373693A4 (en) 2009-01-06 2012-04-25 Curelon Llc COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF ORAL INFECTIONS BY E. COLI
EP2391382B1 (de) 2009-01-29 2014-06-04 Nordmark Arzneimittel GmbH & Co.KG Pharmazeutisches präparat enthaltend lipase bakteriellen ursprungs
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
EP2295039B2 (de) 2009-08-28 2022-10-26 Nordmark Pharma GmbH Verfahren zur Herstellung von Pankreatin-Pellets, insbesondere Pankreatin-Mikropellets, und hiernach hergestellte Pankreatin-Pellets
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
EA029101B1 (ru) 2010-10-01 2018-02-28 Апталис Фарма Лимитид Составы с низкой дозой панкрелипазы и кишечнорастворимым покрытием
EP2489349B1 (de) 2011-02-17 2014-05-28 Nordmark Arzneimittel GmbH & Co.KG Pankreatin-Pellets, insbesondere Pankreatin-Mikropellets, und Verfahren zu deren Herstellung
DE202011000728U1 (de) 2011-03-30 2011-06-09 Nordmark Arzneimittel GmbH & Co. KG, 25436 Pankreatin-Pellets, insbesondere Pankreatin-Mikropellets
ES2726978T3 (es) 2011-04-21 2019-10-11 Curemark Llc Compuestos para el tratamiento de trastornos neuropsiquiátricos
US9976171B2 (en) 2011-08-08 2018-05-22 Allergan Pharmaceuticals International Limited Method for dissolution testing of solid compositions containing digestive enzymes
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
ES2784227T3 (es) 2013-08-09 2020-09-23 Allergan Pharmaceuticals Int Ltd Composición de enzimas digestivos adecuada para la administración entérica
AU2015275860A1 (en) 2014-06-19 2016-11-03 Aptalis Pharma Ltd. Methods for removing viral contaminants from pancreatic extracts
DE102015119006A1 (de) 2015-11-05 2017-05-11 Nordmark Arzneimittel Gmbh & Co. Kg Verfahren zur Reduzierung der Belastung von Pankreatin mit Mikroorganismen
DE102017104482A1 (de) 2017-03-03 2018-09-06 Nordmark Arzneimittel Gmbh & Co. Kg Pharmazeutische Zusammensetzung umfassend Pankreatin und einen lipasehaltigen Überzug
FR3079146B1 (fr) * 2018-03-23 2020-04-17 Karim Ioualalen Formulation gastroprotectrice de complexes d’enzymes permettant de restaurer la fonction digestive.
MD4900B1 (ro) * 2020-06-10 2024-08-31 Kusum Healthcare Private Limited Compoziţie farmaceutică de pancreatină şi procedeu de preparare a acesteia
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3956483A (en) * 1968-10-24 1976-05-11 Wilson Pharmaceutical & Chemical Corporation Preparing pancreatin
FR2059978A1 (en) * 1969-08-20 1971-06-11 Sogeras Enteric coating of sensitive medicaments inp
JPS4946073B1 (ko) * 1970-04-08 1974-12-07
JPS57791B2 (ko) * 1973-11-23 1982-01-07
DE2512746C3 (de) * 1975-03-22 1980-04-24 Kali-Chemie Pharma Gmbh, 3000 Hannover Verfahren zur Herstellung von keimarmem, faserfreiem Pankreatin
GB1509866A (en) * 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
DE2923279C2 (de) * 1979-06-08 1987-07-09 Kali-Chemie Pharma Gmbh, 3000 Hannover Verfahren zur Herstellung von Pankreatin-Pellets und diese enthaltende Arzneimittel
DE3377506D1 (en) * 1982-12-30 1988-09-01 Nordmark Arzneimittel Gmbh Process for obtaining pancreatin
EP0166315B1 (de) * 1984-06-19 1989-08-23 BASF Aktiengesellschaft Magensaftresistent überzogene zylindrische Pankreatin-Mikrotabletten
DE3445301A1 (de) * 1984-12-12 1986-06-12 Hoechst Ag, 6230 Frankfurt Pankreasenzympraeparate und verfahren zu deren herstellung

Also Published As

Publication number Publication date
KR910009282A (ko) 1991-06-28
AU638784B2 (en) 1993-07-08
DE69007055T2 (de) 1994-08-25
US5674532A (en) 1997-10-07
JPH03172181A (ja) 1991-07-25
AU6870191A (en) 1991-06-26
JP3025528B2 (ja) 2000-03-27
EP0436110B1 (en) 1994-03-02
ATE102026T1 (de) 1994-03-15
EP0436110A1 (en) 1991-07-10
CA2030581C (en) 2000-06-27
KR100229754B1 (ko) 1999-11-15
DE69007055D1 (de) 1994-04-07
CA2030581A1 (en) 1991-05-25
US5861177A (en) 1999-01-19
DK0436110T3 (da) 1994-06-20
PH30058A (en) 1996-11-08
WO1991007948A1 (en) 1991-06-13
ES2050340T3 (es) 1994-05-16

Similar Documents

Publication Publication Date Title
PH30058A (en) Pancreation preparations
ES8603753A1 (es) Procedimiento de fabricacion de comprimidos efervescentes
GB9005895D0 (en) Process for concentrating specimens by evaporation of the solvent and a centrifugal evaporator-concentrator for carrying out said process
EP0356484A4 (en) PROCESS FOR THE PREPARATION OF PRODUCTS DERIVED FROM ALOES.
HUT54885A (en) Process for producing liofilized pharmaceutical compositions containing active components
EP0380931A3 (de) Verfahren zur kontinuierlichen Trocknung von hydrophilen Polymergelen
ATE40647T1 (de) Extraktionsverfahren von propolis, danach erhaltenes wasserloesliches getrocknetes pulver aus propolis, propolisenthaltende kosmetische und pharmazeutische praeparate.
ES8303111A1 (es) Un procedimiento y su correspondiente dispositivo para acelerar la disolucion de medicamentos liozilizados poco solu- bles a base de proteinas.
EP0239172A3 (en) Improved spray dried lactose and process for preparing the same
DE3767998D1 (de) Clodronat-haltige arzneimittel und verfahren zur herstellung derselben.
IE42073L (en) Tea extract
GB1417899A (en) Process for the dehydration and granulation of manure-based fertilizers
IE41346B1 (en) Preparation of meat analogues
JPS643126A (en) Androgen acceptor bonding inhibitor
FR2613223B1 (fr) Forme galenique se presentant sous la forme de grains hydrosolubles, en particulier a base d'un extrait sec de ginkgo biloba, et son procede de preparation
AU2306288A (en) Process for extracting physiologically active substance from pine seed shells and antiinfectant prepared mainly from the extract
EP0281953A3 (en) Process for granulating water-soluble fertilizers with a high proportion of kieserite
GR3007353T3 (ko)
JPS522877A (en) Process and apparatus for granulating of high molecular coagulating ag ents
AU2771689A (en) A method for decontaminating a material and an assembly for carrying out said method
EP0256695A3 (en) Product for use as an osteoinductive agent, and method of preparing same
JPS5239503A (en) Method of drying metallurgical materials
JPS6438206A (en) Preparation of porous ceramic plate
DE3067343D1 (en) Process for producing dry extract of colostrum, dry extract obtained and use thereof
EP0568026A3 (en) Piroxicam tablets and production process thereof

Legal Events

Date Code Title Description
PF Patent in force
AS Change of ownership

Owner name: SANDOZ AG

Free format text: FORMER OWNER(S): SANDOZ GMBH

CHPA Change of a particular in the register (except of change of ownership)
PE Patent expired

Effective date: 20101122